Page 11234..1020..»

Archive for the ‘Gene Therapy Research’ Category

Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting – Business Wire

BOSTON--(BUSINESS WIRE)--Akouos, a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association for Research in Otolaryngology (ARO), being held January 25 to January 29, 2020 in San Jose, CA.

Akouos continues to advance our platform for inner ear disorders, and we are excited to share our progress with the scientific community, said Greg Robinson, Ph.D., chief scientific officer of Akouos. The data presented at ARO further substantiates Akouoss use of AAVAnc80 vector technology and its potential to address many forms of hearing loss.

SYMPOSIUM

Title: The Adeno-associated Viral Anc80 (AAVAnc80) Vector - Precision Genetic Medicines to Address Hearing LossPresenter: Michelle Valero, Ph.D., Director, Anatomy & Physiology, AkouosSession: Symposium 11Date and Time: Saturday, January 25, 3 p.m. (PST)

POSTER PRESENTATIONS

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Olive Baboons (Papio anubis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Cynomolgus Macaques (Macaca fascicularis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: Dual Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Non-human PrimatesDay and Time: Monday, January 27, 1 p.m. (PST)

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to improve and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. For more information, please visit http://www.akouos.com.

About AAVAnc Technology

Ancestral AAV (AAVAnc) technology was developed in the laboratory of Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Harvard Medical School. AAVAnc technology uses computational and evolutionary methods to predict novel conformations of the adeno-associated viral particle. AAVAnc80, one of 40,000 AAVAnc vectors, has demonstrated preliminary safety and effective gene delivery in both mice and non-human primates in numerous preclinical studies.

See the original post:
Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting - Business Wire

Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference – StreetInsider.com

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

Go here to read the rest:
Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference - StreetInsider.com

Global Cancer Therapies Industry – GlobeNewswire

New York, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Therapies Industry" - https://www.reportlinker.com/p05817674/?utm_source=GNW Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities. - Against the backdrop of tumor diversity, the universal "one size fits all" therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancers diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancers mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called "alternative splicing. Aberrations in alternative splicing are linked to cancers progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancers biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide. - Competitors identified in this market include, among others, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company , F. Hoffmann-La Roche Ltd., Glaxosmithkline Plc, Johnson & Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc.,Takeda Pharmaceutical Company Limited.

Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

CANCER THERAPIES MCP-1MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Cancer Therapies: An Outlook Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market By Cancer Type USA Leads the Cancer Therapies Market Biotherapies to Drive Growth Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth Total Number of New Cancer Cases by Type: 2018 Total Number of Cancer Deaths by Type: 2018 Cancer Incidence by Region: 2018 Cancer Mortality by Region: 2018 Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018 Cancer Research Spending Continues to Witness Growth Number of FDA-Approved Cancer Drugs: 2010-2018 Select Cancer Drug Approvals in 2019 Select Cancer Drug Approvals in 2018 Cancer Drug Pipeline to Change the Pharma Landscape Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019 Global Competitor Market Shares Cancer Therapies Competitor Market Share Scenario Worldwide (in %): 2019 Select Leading Cancer Drugs Worldwide by Sales: 2018

2. FOCUS ON SELECT PLAYERS AbbVie, Inc. (USA) Amgen, Inc. (USA) Astellas Pharma, Inc. (Japan) AstraZeneca Plc. (UK) Bayer AG (Germany) Bristol-Myers Squibb Company (USA) Select Late Stage Compounds in Bristol-Myers Squibb Companys Oncology Pipeline (As of 2019) Celgene Corporation (USA) Eli Lilly and Company (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Glaxosmithkline Plc (UK) Johnson & Johnson Services, Inc. (USA) Merck KGaA (Germany) Novartis AG (Switzerland) Pfizer, Inc. (USA) Takeda Pharmaceutical Company Limited (Japan)

3. MARKET TRENDS & DRIVERS Industry Focuses on New Approaches to Treat Cancer Recent Advancements in Cancer Drug Discovery A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team Lymphoma Therapy Developed by BeiGene Secures US FDA Approval New Linker Technology for Enhancing Stability of ADCs Personalized Medicine Gains Importance Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care North American Companion Diagnostics Market (2019) European Companion Diagnostics Market by Disease Area (2019) Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs Combination Therapy: A Double Whammy Success Patent Expiries of Branded Drugs to Trigger Generic Competition Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer Development of Novel Drug Candidates and Potential Therapies Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies Rise in Patient Assistance Programs (PAPs) Top Financial Concerns for Cancer Patients: Ranked In Order of Influence Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses Growth Drivers and Restraints Demographics & Lifestyles Raise the Risk of Cancer Percentage Breakdown of New Cases for All Cancers by Gender (2019) Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019) Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019) Unmet Needs Leave Scope for Further Research and Development Low Entry Barriers in Cancer Research Encourages Breakthrough Developments Increasing Investments by National Health Authorities NCI Funding for Cancer Research (2002, 2008, 2014 and 2020) Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth Molecular Imaging of Cancer: Critical in Improving Patient Outcomes Innovations, Improvements, and Approvals Propel Growth Select Cancer Drug Approvals (2018 & 2019) Emerging Challenges in Cancer Drug Development Drug Failures Deter Prospects of New Therapies High Prices of Targeted Therapies Act as a Speed Breaker Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016 Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation Limited Tumor Specificity and Toxicity Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance Reduced Smoking Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018 Reimbursement Coverage Remains a Major Challenge Increase in Multidrug Resistance Stringent Regulations Delay Market Approval Challenges Encountered in Clinical Trials Overview of Cancer Therapy Segments Immunotherapy: A Promising Segment Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019 Monoclonal Antibodies for Cancer Treatment Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment Vaccines: A Promising Future Area of Cancer Therapeutics Approved Therapeutic Cancer Vaccines Worldwide CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients Immune Cells for Cancer Treatment UK Researchers New Approach Holds Potential to Boost Immunotherapies Targeted Therapy: An Overview Types of Targeted Therapy Chemotherapy: An Overview Types of Chemotherapy Risks Associated with Chemotherapy Hormone Therapy Drug Classes in Hormone Therapy Cancer Types, Approved and Pipeline Drugs Prostate Cancer Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018 Select General Risk Factors and their Relative Risk Rate in Prostate Cancer Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC) Prostate Cancer Phase IV Completed Clinical Trials with Results Lung Cancer Age-Standardized Lung Cancer Rates for Select Countries Age-Standardized Lung Cancer Rates in Men for Select Countries Age-Standardized Lung Cancer Rates in Women for Select Countries Select FDA-Approved Non-Small Cell Lung Cancer Drugs Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019 Select Phase III Completed Clinical Trials with Results: As of December 30, 2019 Breast Cancer Select FDA Approved Breast Cancer Drugs Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Renal Cancer Select FDA-Approved Renal Cell Carcinoma Drugs Cervical Cancer Colorectal Cancer Select FDA-Approved Colorectal Cancer Drugs Skin Cancer Skin Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Pancreatic Cancer Non-Hodgkins Lymphoma Leukemia Standard Approved Mode of Therapy for AML by Age Group Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Bladder Cancer Endometrial Cancer

4. GLOBAL MARKET PERSPECTIVE Table 1: Cancer Therapies Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 2: Cancer Therapies Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 Table 3: Cancer Therapies Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Chemotherapy (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 5: Chemotherapy (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 6: Chemotherapy (Treatment Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Targeted Therapy (Treatment Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 8: Targeted Therapy (Treatment Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 9: Targeted Therapy (Treatment Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Immunotherapy (Treatment Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 11: Immunotherapy (Treatment Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 12: Immunotherapy (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 13: Hormonal Therapy (Treatment Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2to 2025 Table 14: Hormonal Therapy (Treatment Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 15: Hormonal Therapy (Treatment Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 16: Other Treatment Types (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 17: Other Treatment Types (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 18: Other Treatment Types (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 19: Blood Cancer (Cancer Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 Table 20: Blood Cancer (Cancer Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 21: Blood Cancer (Cancer Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 Table 22: Breast Cancer (Cancer Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 Table 23: Breast Cancer (Cancer Type) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 Table 24: Breast Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 25: Prostate Cancer (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 26: Prostate Cancer (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 27: Prostate Cancer (Cancer Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 28: Gastrointestinal Cancer (Cancer Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 29: Gastrointestinal Cancer (Cancer Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 30: Gastrointestinal Cancer (Cancer Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 31: Gynecologic Cancer (Cancer Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 32: Gynecologic Cancer (Cancer Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 33: Gynecologic Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 34: Lung Cancer (Cancer Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 Table 35: Lung Cancer (Cancer Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 36: Lung Cancer (Cancer Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 37: Other Cancer Types (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 38: Other Cancer Types (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 39: Other Cancer Types (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Overview Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market Estimated Number of New Cancer Cases and Deaths in the US (2019) Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018 Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent Personalized Medicine Gathers Momentum for Cancer Treatment in the US A Surging US Prostate Cancer Therapeutics Market Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care CMS Hikes Reimbursement Rate for CAR-T Therapy Market Analytics Table 40: United States Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 41: Cancer Therapies Market in the United States by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 42: United States Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 43: United States Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 44: Cancer Therapies Market in the United States by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 45: United States Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 CANADA Number of New Cancer Cases in Canada: 2019 Market Analytics Table 46: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 47: Canadian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 48: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 49: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 50: Canadian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 51: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 JAPAN Table 52: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 53: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 54: Japanese Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 55: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 56: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 57: Japanese Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 CHINA Cancer Therapies Market: Overview Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products Market Analytics Table 58: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 59: Cancer Therapies Historic Market Analysis in China in US$ Million by Treatment Type: 2009-2017 Table 60: Chinese Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 61: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 62: Cancer Therapies Historic Market Analysis in China in US$ Million by Cancer Type: 2009-2017 Table 63: Chinese Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 EUROPE Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018 Market Analytics Table 64: European Cancer Therapies Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 65: Cancer Therapies Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 Table 66: European Cancer Therapies Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 68: Cancer Therapies Market in Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 69: European Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 70: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 71: Cancer Therapies Market in Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 72: European Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 FRANCE Table 73: Cancer Therapies Market in France by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 74: French Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 75: French Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 76: Cancer Therapies Market in France by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 77: French Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 78: French Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 GERMANY Table 79: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 80: German Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 81: German Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 82: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 83: German Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 84: German Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ITALY Table 85: Italian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 86: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Treatment Type: 2009-2017 Table 87: Italian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 88: Italian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 89: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Cancer Type: 2009-2017 Table 90: Italian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED KINGDOM Table 91: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 92: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 93: United Kingdom Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 94: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 95: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 96: United Kingdom Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 SPAIN Table 97: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 98: Spanish Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 99: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 100: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 101: Spanish Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 102: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 RUSSIA Table 103: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 104: Cancer Therapies Market in Russia by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 105: Russian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 106: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 107: Cancer Therapies Market in Russia by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 108: Russian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF EUROPE Table 109: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 110: Cancer Therapies Market in Rest of Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 111: Rest of Europe Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 112: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 113: Cancer Therapies Market in Rest of Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 114: Rest of Europe Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ASIA-PACIFIC An Insight into Asia-Pacific Market for Cancer Therapies Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019 Market Analytics Table 115: Asia-Pacific Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 116: Cancer Therapies Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 Table 117: Asia-Pacific Cancer Therapies Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 118: Cancer Therapies Market in Asia-Pacific by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 119: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 120: Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 121: Cancer Therapies Market in Asia-Pacific by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 122: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 123: Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 AUSTRALIA Table 124: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 125: Australian Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 126: Australian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 127: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 128: Australian Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 129: Australian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 INDIA Table 130: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 131: Indian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 132: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 133: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 134: Indian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 135: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 SOUTH KOREA Table 136: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 137: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 138: Cancer Therapies Market Share Distribution in South Korea by Treatment Type: 2009 VS 2019 VS 2025 Table 139: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 140: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 141: Cancer Therapies Market Share Distribution in South Korea by Cancer Type: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 142: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 143: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 144: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 145: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 146: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 147: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 LATIN AMERICA Table 148: Latin American Cancer Therapies Market Trends by Region/Country in US$ Million: 2018-2025 Table 149: Cancer Therapies Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 Table 150: Latin American Cancer Therapies Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 151: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 152: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Treatment Type: 2009-2017 Table 153: Latin American Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 154: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 155: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Cancer Type: 2009-2017 Table 156: Latin American Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 ARGENTINA Table 157: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 158: Cancer Therapies Market in Argentina in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 159: Argentinean Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 160: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 161: Cancer Therapies Market in Argentina in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 162: Argentinean Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 BRAZIL Table 163: Cancer Therapies Market in Brazil by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 164: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 165: Brazilian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 166: Cancer Therapies Market in Brazil by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 167: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 168: Brazilian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 MEXICO Table 169: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 170: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 171: Mexican Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 172: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 173: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 174: Mexican Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 175: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 176: Cancer Therapies Market in Rest of Latin America by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 177: Rest of Latin America Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 178: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2to 2025 Table 179: Cancer Therapies Market in Rest of Latin America by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 180: Rest of Latin America Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 MIDDLE EAST Table 181: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 182: Cancer Therapies Market in the Middle East by Region/Country in US$ Million: 2009-2017 Table 183: The Middle East Cancer Therapies Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 184: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 185: The Middle East Cancer Therapies Historic Market by Treatment Type in US$ Million: 2009-2017 Table 186: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 187: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 188: The Middle East Cancer Therapies Historic Market by Cancer Type in US$ Million: 2009-2017 Table 189: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 IRAN Table 190: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 191: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 192: Iranian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 193: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 194: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 195: Iranian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 ISRAEL Table 196: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 197: Cancer Therapies Market in Israel in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 198: Israeli Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 199: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 200: Cancer Therapies Market in Israel in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 201: Israeli Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 202: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 203: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Treatment Type: 2009-2017 Table 204: Saudi Arabian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 205: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 206: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Cancer Type: 2009-2017 Table 207: Saudi Arabian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED ARAB EMIRATES Table 208: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 209: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 210: Cancer Therapies Market Share Distribution in United Arab Emirates by Treatment Type: 2009 VS 2019 VS 2025 Table 211: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 212: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 213: Cancer Therapies Market Share Distribution in United Arab Emirates by Cancer Type: 2009 VS 2019 VS 2025 REST OF MIDDLE EAST Table 214: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 215: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 216: Rest of Middle East Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 217: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 218: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 219: Rest of Middle East Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 AFRICA Table 220: African Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 221: Cancer Therapies Market in Africa by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 222: African Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 223: African Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 224: Cancer Therapies Market in Africa by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 225: African Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled : 75 (including Divisions/Subsidiaries - 80) Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
Global Cancer Therapies Industry - GlobeNewswire

Global Gene Therapy Market Growth Analysis, Forecasts to 2025:2023: Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon -…

The global "Gene Therapy Market" research report highlights the need for the up-to-date market data for the business management that will offer development and profitability of the global Gene Therapy market. The research report presents all the essential facts and figures on drifts & growths. It emphasizes on technologies & capacities, materials & markets, and unpredictable structure of the Gene Therapy market. In addition, it also highlights the dominating players in the market joined with their market share. The well-established players in the market are Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical, Advantagene.

Click Here To Access The Report: http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html#request-sample

The global Gene Therapy market report portrays best approaches to assess the global Gene Therapy market. It offers the reliable facts and extensive analysis of the global Gene Therapy market. The report presents a summary of the global Gene Therapy industry, embracing categorizations, applications, and industry chain structure. The study also represents a thorough analysis including significant insights, industry-legalized figures, and facts of the global Gene Therapy market.

Furthermore, the study also assesses the principal aspects of the market that entails revenue, demand, gross value, growth rate, cost, capability, market share, import, gross margin, expenditure, export, manufacture, supply, and so on. A number of methodological tools are used in the global Gene Therapy market analysis. It offers a complete analysis of the market statistics and the estimation of the global Gene Therapy industry players along with their market scope.

Read Detailed Index of full Research Study at:http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html

The research report highlights the assessment of its diverse segments. It also offers analysis of main topographies of the global Gene Therapy market. This profound review portrays the existing market development & drifts, key aspects impelling the market expansion, market projections, drivers, limits, and market structure. The market study also offers analysis of every area of the global Gene Therapy market along with its sub-segments. Additionally, the global Gene Therapy market report covers the major product categories and segments Ex vivo, In vivo along with their sub-segments Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others in detail.

In addition, the study emphasizes the leading market players ruling worldwide. It also provides the user with important details such as sales, contact details, product specifications & pictures, and market share. The assessment also embodies previous and expected data and statistics that make the report an extremely precious reference for advertising individuals, advisors, industry executives, sales & product executives, forecasters, and other personals hunting for crucial industry information in readily handy scripts with outstandingly displayed tables, statistics, and graphs.

There are 15 Chapters to display the Global Gene Therapy market

Chapter 1, Definition, Specifications and Classification of Gene Therapy , Applications of Gene Therapy , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Gene Therapy , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Gene Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Gene Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Gene Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Ex vivo, In vivo, Market Trend by Application Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Gene Therapy ;Chapter 12, Gene Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Gene Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: http://www.99strategy.biz/global-gene-therapy-market-2018-2023-industry-overview.html#inquiry-for-buying

Reasons for Buying Gene Therapy market

This report provides pin-point analysis for changing competitive dynamicsIt provides a forward looking perspective on different factors driving or restraining market growthIt provides a six-year forecast assessed on the basis of how the market is predicted to growIt helps in understanding the key product segments and their futureIt provides pin point analysis of changing competition dynamics and keeps you ahead of competitorsIt helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Read more from the original source:
Global Gene Therapy Market Growth Analysis, Forecasts to 2025:2023: Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon -...

He was called ‘the boy in the bubble.’ His short life gave insights into a rare illness – Stuff.co.nz

He ate, played and learned like any other kid. But David Vetter's life unfolded in a series of unusual environments: plastic, bubblelike enclosures that protected him from germs. He had severe combined immunodeficiency (SCID), and even a seemingly harmless germ could kill him.

The subject of pop culture scrutiny and medical fascination, David was called "the boy in the bubble" by the US media. SCID is rare and often fatal; it affects about 1 in 58,000 infants.

The disorder is created by genetic mutations that cause patients to produce too few of the immune cells that protect the body from infection. In healthy immune systems, T and B cells known as lymphocytes attack foreign organisms.

READ MORE:*Doctors use HIV in gene therapy to fix 'bubble boy*Eight-month old Kiwiboy facing life in a bubble*'Remarkable' progress in finding cure for HIV

People with SCID lack these critical immune defences.

David, who lived in the US state of Texas, wasn't supposed to grow up in isolation. But while doctors waited for a cure, they decided to keep him in a sterile environment.

Raising a child in plastic isolation was developmentally risky and ethically questionable. But exposing David to the outside world meant death. Doctors thought a cure was just around the corner. Meanwhile, David became a long-term research subject.

GETTY IMAGES

David Vetter, who was born with severe combined immunodeficiency (SCID), plays in the enclosed plastic environment that he was forced to live in to survive. His short life provided insights into how SCID works.

Precocious, bright and sociable, he challenged expectations at every turn. (He did have visual problems that stemmed from being raised entirely in enclosed spaces, and he exhibited symptoms of depression.)

During his long confinement, medical technology progressed. But an experimental bone marrow transplant from his sister was David's death sentence. Undetected Epstein-Barr virus in her marrow triggered lymphoma. He died of the cancer in 1984 at age 12.

Because he was brought up in a sterile environment, his death allowed researchers to confirm a long-standing hypothesis that Epstein-Barr can cause cancer.

David's short life also provided insights into how SCID works. Better bone marrow screening now means more transplants are successful. According to the Immune Deficiency Foundation, 91 per cent of infants who are diagnosed early and given transplants by age 3- months survive.

Today, David's medical records and personal papers are held by the Smithsonian Institution in Washington DC. Perhaps the most touching of the museum's artifacts are his Star Warsaction figures a painful reminder of the child at the centre of a medical drama he could not control.

View original post here:
He was called 'the boy in the bubble.' His short life gave insights into a rare illness - Stuff.co.nz

Exclusive Growth on Gene Therapy Industry Market Forecast by 2020-2026 | Top Key Players: Bluebird Bio,Sangamo,Spark Therapeutics – Briotainment

A new statistical study of the Gene Therapy Industry market was recently published by Healthcare Intelligence Market. Primary and secondary research techniques have been used to provide effective and accurate data to make informative decisions in the businesses.

At the same time, we classify different Sports Drug Testing Device based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What is more, the Gene Therapy Industry industry development trends and marketing channels are analyzed.

Get Sample copy of Report@ https://www.healthcareintelligencemarkets.com/request_sample.php?id=113738

Leading Key Players Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.Advantagene

The global competitive landscape has been elaborated on the basis of analysis of several companies. For an effective analysis, different tools such as Porters five and SWOT analysis have been used. This research report also looks at the latest developments in technologies and business sectors like Gene Therapy Industry. Techniques that will come in handy to explore global opportunities have also been listed in the report.

Gene Therapy Industry Market segmentation, by regions:

North America

Europe

Asia Pacific

Middle East & Africa

Latin America

Others

Special discount on this report@ https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=113738

Market Report includes major TOC points:

Gene Therapy Industry Overview

Global Economic Impact on Industry

Global Market Competition by Manufacturers

Global Production, Revenue (Value) by Region

Global Supply (Production), Consumption, Export, Import by Regions

Global Production, Revenue (Value), Price Trend by Type

Global Market Analysis by Application

Manufacturing Cost Analysis

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Gene Therapy Industry Forecast

Objective of Studies:

1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Gene Therapy Industry market.

2. To provide insights about factors affecting the market growth. To analyze the Gene Therapy Industry market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.

3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.

4. To provide country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Gene Therapy Industry market.

The statistical survey report also offers numerous approaches to discover global opportunities for increasing businesses rapidly. It gives a comprehensive analysis of the global Gene Therapy Industry market which calculates different verticals of businesses such as, production capacity, local consumers, global and local clients, and potential customers.

Enquiry before buying:- for more information ask our expert@ https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=113738

About US

HealthCare Intelligence Markets Reports provides market intelligence & consulting services to a global clientele spread over 145 countries. Being a B2B firm, we help businesses to meet the challenges of an ever evolving market with unbridled confidence. We craft customized and syndicated market research reports that help market players to build game changing strategies. Besides, we also provide upcoming trends & future market prospects in our reports pertaining to Drug development, Clinical & healthcare IT industries. Our intelligence enables our clients to take decisions with which in turn proves a game-changer for them. We constantly strive to serve our clients better by directly allowing them sessions with our research analysts so the report is at par with their expectations.

Contact us:

Marvella Lit

Phone no: +1 (888) 616-2766

Address: 90 State Office Center

90 State Street Suite 700, Albany, NY 12207

sales@healthcareintelligencemarkets.com

http://www.healthcareintelligencemarkets.com

Here is the original post:
Exclusive Growth on Gene Therapy Industry Market Forecast by 2020-2026 | Top Key Players: Bluebird Bio,Sangamo,Spark Therapeutics - Briotainment

-$0.63 Earnings Per Share Expected for Axovant Gene Therapies Ltd (NASDAQ:AXGT) This Quarter – Riverton Roll

Analysts predict that Axovant Gene Therapies Ltd (NASDAQ:AXGT) will post earnings per share (EPS) of ($0.63) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Axovant Gene Therapies earnings, with estimates ranging from ($0.66) to ($0.57). Axovant Gene Therapies reported earnings of ($2.16) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 70.8%. The business is expected to report its next quarterly earnings report on Thursday, February 6th.

On average, analysts expect that Axovant Gene Therapies will report full year earnings of ($3.56) per share for the current fiscal year, with EPS estimates ranging from ($5.76) to ($1.84). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.32) per share, with EPS estimates ranging from ($2.84) to ($1.20). Zacks Investment Researchs earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Axovant Gene Therapies.

Axovant Gene Therapies (NASDAQ:AXGT) last posted its earnings results on Friday, November 8th. The company reported ($0.61) earnings per share for the quarter, topping the Thomson Reuters consensus estimate of ($1.15) by $0.54.

Several equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Axovant Gene Therapies from a hold rating to a strong-buy rating and set a $6.00 target price on the stock in a report on Wednesday, November 13th. ValuEngine upgraded shares of Axovant Gene Therapies from a hold rating to a buy rating in a report on Friday. Finally, Chardan Capital raised their price objective on shares of Axovant Gene Therapies from $10.00 to $15.00 and gave the stock a buy rating in a report on Monday, October 28th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $24.72.

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its holdings in shares of Axovant Gene Therapies by 955.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the companys stock worth $27,000 after acquiring an additional 3,821 shares during the period. Barclays PLC acquired a new stake in shares of Axovant Gene Therapies during the third quarter worth $65,000. Jane Street Group LLC raised its holdings in shares of Axovant Gene Therapies by 28.8% during the second quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the period. Finally, BlackRock Inc. acquired a new stake in shares of Axovant Gene Therapies during the second quarter worth $1,482,000. Institutional investors and hedge funds own 14.80% of the companys stock.

AXGT opened at $4.95 on Tuesday. The firms fifty day moving average is $5.18 and its two-hundred day moving average is $6.20. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.69. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $19.60.

About Axovant Gene Therapies

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Read More: What is a capital gain?

Get a free copy of the Zacks research report on Axovant Gene Therapies (AXGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

See the original post:
-$0.63 Earnings Per Share Expected for Axovant Gene Therapies Ltd (NASDAQ:AXGT) This Quarter - Riverton Roll

New Gene Therapy In Mice Could Offer Lasting Protection Against Nerve Agents – Discover Magazine

Chemical nerve agents are some of the most horrifying tools of war today. The compounds kill by paralyzing the nervous system and have been used in devastating attacks on civilians or soldiers in war zones. And they can appear, albeit in smaller doses, in pesticides used in developing countries, endangering farm workers after prolonged exposure.

For years, researchers have been searching for antidotes or treatments that could save those afflicted by these deadly chemicals. In a paper out today in Science Translational Medicine, a team from the U.S. Army Medical Research Institute of Chemical Defense has announced a potential solution: a gene therapy that grants immunity to the effects of nerve agents like sarin.

Nerve agents are compounds that interfere with a persons nervous system. As the chemicals pass through a body after exposure to skin or through inhalation, they disable an enzyme called acetylcholinesterase thats needed for communication between neurons. The results are devastating: An affected person will involuntarily discharge tears, saliva, urine and feces, experience seizures and paralysis, and rapidly die from asphyxiation.

Scientists have found that that certain enzymes in the body called bioscavengers find and break down the toxic nerve agent molecules in the body, disabling them and preventing harm. In earlier work, the Maryland-based team found that a certain variation of a enzyme made in the liver called PON1 was particularly effective. When injected into a mouse, it granted immunity to nerve agents effects temporarily. But now the team has used a gene therapy to coax the body to make the enzyme, continually, on its own.

In the new study, the team focused on a gene that carries the instructions for the most potent version of the PON1 enzyme, called PON1-IF11. By putting the gene into a virus a common technique used to deliver a gene to a host they were able to successfully introduce PON1-IF11 into mice. After injecting the rodents, just once, with the viral vector containing the gene, the mice became immune to the common nerve agents tabun, sarin, cyclosarin and soman.

The results were encouraging. "[I felt] great satisfaction and excitement," said Venkaiah Betapudi, a molecular cell biologist and first author of the paper, in an email. "[I'm] anxious to take this work to next level and make this modern medicine available to our soldiers."

The immunity lasted for the full 5 months of the study, but in theory, it should last for the lifetime of the animal.

As long as the animal lives, the enzyme is there," says Nageswararao Chilukuri, who leads the research group. "We stopped [the study] at five months after the injection, but if we had measured 6 months, 7 months, 8 months I think it will be there. We just dont have the data to show it.

But Chilukuri emphasizes that were a long way from seeing anything close to a nerve agent vaccine for humans that uses the new technique.

Gene therapy products are only for diseases right now, he explains. We are trying to use this for healthy people. We dont know the long-term safety profile of the viral vectors. We have to be absolutely sure that when we inject a virus, that 50 years from now it will not be toxic or cause any complications.

But when it does come of age, it could have broad applications. "This modern medicine can protect sniffing dogs in the battlefield and TSA and border security operations," says Betapudi.

Luckily, many researchers studying gene therapy more broadly are asking these questions too, so answers may soon emerge regarding the safety of this type of gene therapy.

[Editor's note: This post has been updated to include comments from Venkaiah Betapudi, and to clarify the respective contributions of Nageswararao Chilukuri and Betapudi.]

Originally posted here:
New Gene Therapy In Mice Could Offer Lasting Protection Against Nerve Agents - Discover Magazine

Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting – Yahoo Finance

Data further supports Akouoss use of AAVAnc80 technology delivered via intracochlear administration to potentially improve hearing

Akouos, a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association for Research in Otolaryngology (ARO), being held January 25 to January 29, 2020 in San Jose, CA.

"Akouos continues to advance our platform for inner ear disorders, and we are excited to share our progress with the scientific community," said Greg Robinson, Ph.D., chief scientific officer of Akouos. "The data presented at ARO further substantiates Akouoss use of AAVAnc80 vector technology and its potential to address many forms of hearing loss."

SYMPOSIUM

Title: The Adeno-associated Viral Anc80 (AAVAnc80) Vector - Precision Genetic Medicines to Address Hearing LossPresenter: Michelle Valero, Ph.D., Director, Anatomy & Physiology, AkouosSession: Symposium 11Date and Time: Saturday, January 25, 3 p.m. (PST)

POSTER PRESENTATIONS

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Olive Baboons (Papio anubis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: The Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Cynomolgus Macaques (Macaca fascicularis)Day and Time: Monday, January 27, 1 p.m. (PST)

Title: Dual Adeno-associated Viral Anc80 Vector Efficiently Transduces Inner Ear Cells in Non-human PrimatesDay and Time: Monday, January 27, 1 p.m. (PST)

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to improve and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. For more information, please visit http://www.akouos.com.

About AAVAnc Technology

Ancestral AAV (AAVAnc) technology was developed in the laboratory of Luk Vandenberghe, Ph.D., Director of the Grousbeck Gene Therapy Center at Harvard Medical School. AAVAnc technology uses computational and evolutionary methods to predict novel conformations of the adeno-associated viral particle. AAVAnc80, one of 40,000 AAVAnc vectors, has demonstrated preliminary safety and effective gene delivery in both mice and non-human primates in numerous preclinical studies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005380/en/

Contacts

Katie Engleman, 1ABkatie@1abmedia.com

Read the original:
Akouos Announces New Data at the Association for Research in Otolaryngology Midwinter Meeting - Yahoo Finance

Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference – Yahoo Finance

Decibel Therapeutics, a development-stage biotechnology company creating novel therapeutics for hearing loss and balance disorders, will present new findings from several of their drug discovery and development programs at the 43rd annual meeting of the Association for Research in Otolaryngology, which is being held from January 25-29 in San Jose, CA.

Data to be presented at the conference showcase how Decibels drug discovery and translational platform is enabling the development of an array of therapeutic programs, including DB-020 to treat cisplatin-induced ototoxicity and a gene therapy to treat congenital deafness caused by a deficiency in the otoferlin gene. In an invited symposium, Jonathon Whitton, Au.D., Ph.D., director of clinical development, will highlight how Decibel has leveraged its industry-leading, single-cell genomics and bioinformatics capabilities as part of a broader gene therapy platform to optimize therapeutic solutions for hearing loss and balance disorders.

"Over the past year, we have made significant advances in a number of our programs. These developments demonstrate the strength of our unique approach and will continue to enable our efforts in restoration and regenerative medicine approaches to the inner ear," said John Lee, executive vice president, pharmaceutical development.

The Decibel team will have a total of eight posters and presentations during this years meeting.

Podium Presentations

SYMP 12 | Moving Gene Therapies for Hearing Loss into the ClinicDate & Time: Saturday, January 25, 3:15 p.m. PT

PD 35 | Dissecting the Differentiation Fates of Hair Cells in the Vestibular Sensory Epithelia during Mouse Inner Ear Development using Single Cell TranscriptomicsDate & Time: Sunday, January 26, 11:00 a.m. PT

Poster Presentations

PS 60 | Development of Middle-Ear-Muscle Reflex (MEMR) Biomarker in Mouse

PS 143 | Multivariate Polygenic Risk Scores Identify Individuals At-Risk for and Protected from Hearing Loss

PS 184 | Natural History and Disease Progression in Two Rodent Models of Monogenic Hearing Loss

PS 463 | DB-020 Protects Cells from Cisplatin Cytotoxicity in vitro and Hair Cells in a Guinea Pig Model of Cisplatin Induced Ototoxicity

PS 692 | Tailored AAV-based Transgene Expression in the Inner Ear with Cell Type-Specific Promoters

PS 714 | Characterization of an Acute and Cyclic Cisplatin-Induced Hearing Loss in Male Fischer-344 Rats

About Decibel Therapeutics, Inc.Decibel Therapeutics, a development-stage biotechnology company, has established the worlds first comprehensive drug discovery, development and translational research platform for hearing and balance disorders. Decibel is advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibels lead therapeutic candidate, DB-020, is being investigated for the prevention of ototoxicity associated with cisplatin chemotherapy. For more information about Decibel Therapeutics, please visit decibeltx.com or follow @DecibelTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005232/en/

Contacts

Matthew Corcoran, Ten Bridge Communicationsmcorcoran@tenbridgecommunications.com (617)-866-7350

Read more here:
Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference - Yahoo Finance

A cell and gene therapy development center is taking 680K square feet at KOP’s Discovery Labs – Technical.ly

At the Bio International Convention held last year in Philadelphia, The Discovery Labs announced it was opening 1.6 million square feet of coworking space and collaborative labs for healthcare, life sciences and tech companies out of GlaxoSmithKlinesformer campus in King of Prussia.

About half a year later, nearly all its square footage has been accounted for, Audrey Greenberg, executive managing director of the Discovery Labs, told Technical.ly.

Included is a big get for the region: The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a contract development and manufacturing organization and specialty investment company, the Discovery Labs announced this week.

The Center for Breakthrough Medicines leased 680,000 square feet of Discovery Labs facility to provide pre-clinical through commercial manufacturing of cell and gene therapies, including process development, plasmid DNA, viral vectors, cell banking, cell processing and support testing capabilities.

Its goal is to to alleviate the critical lack of capacity that is preventing patients from accessing critically needed cell and gene therapies, Discovery Labs said.

Today brilliant scientists are advancing an unprecedented number of gene and cell therapy drug candidates. The real tragedy, however, is a scarcity of manufacturing know-how, which is complex and expensive, said Alex Karnal, partner and managing director of Deerfield Management and a board member of the Discovery Labs, in a statement. It is hoped that the Center for Breakthrough Medicines will help realize the promise of cell and gene therapies in time to treat the many patients who need them.

TheCenter for Breakthrough Medicines has initiated a substantial hiring effort, with plans to hire more than 2,000 team members within the next 30 months in positions like Ph.D. scientists, manufacturing experts, lab technicians and support staff.

Greenberg called the company an end-to-end solution for companies that are looking to manufacture their solutions and products.

There wasnt really space for that to happen, and were in a biotech epicenter, she said. Companies can grow within our space.

An early rendering of The Discovery Labs. (Courtesy image)

First leases within the 1.6 million square feet across campus will likely be taken up by 10 to 20 companies in the first quarter of 2020. Many, including the Center for Breakthrough Medicines, will move into the space in Q3 or Q4 of 2020, after renovations are complete and labs are outfitted to each companys needs.

The campus is also getting a biotech incubator, Unite IQ, which will offer space to emerging life sciences startups with resources needed to initiate business operations. Unite IQ tenants will be able to use the discovery, development, testing and manufacturing capabilities of the Center for Breakthrough Medicines and tech transfer from research lab to large-scale production.

Currently, Philadelphia is home to the only Discovery Labs campus, but the company is looking toward expanding with locations on the West Coast, in Asia and in Europe.

The region is continuously growing as a hub for life sciences, andGreenberg cited King of Prussias proximity to top cell and gene therapy talent, area hospitals and patient pools as important to the Discovery Labs. Also important, she noted, was access to the Philadelphia International Airport (and its supply-chain abilities with cold storage function for transporting cell therapies).

The work is extremely important to Greenberg personally, she said.

Theres an immediacy to this work, in this industry thats working on cures for patients who are dying every day, she said. To me, this work is doing well by doing good.

See the rest here:
A cell and gene therapy development center is taking 680K square feet at KOP's Discovery Labs - Technical.ly

5 Predictions for Philadelphia’s Cell and Gene Therapy Sector in 2020 – Philadelphia magazine

News

Independence Health Group CEO and Chamber of Commerce chairman Dan Hilferty shares his forecast for the growth of the region's bustling health care ecosystem.

Dan Hilferty is the chairman of the Chamber of Commerce for Greater Philadelphia and the CEO of Independence Health Group.

Its been one year since the Chamber of Commerce for Greater Philadelphia, through its CEO Council for Growth and with its partners and collaborators, formally launched the Cell & Gene Therapy and Connected Health Initiative to leverage our regions assets and existing strengths.

My predictions for the initiative and the industry for the coming year are:

Groundbreaking discoveries with origins here have resulted in six FDA-approved therapies since 2017. In 2020, our outstanding research institutions will continue to build on the history of discovery and the recent successes here, leading to more breakthroughs to benefit patients and improve and save lives.

Increased awareness of Greater Philadelphia as a center of innovative excellence in R&D, health care and life sciences will continue to result in an increase in the number of companies locating here as they seek to build out where there is talent, lab space, and research partnership opportunities all close by.

The Chambers Select Greater Philadelphia Council will continue to be a key leader in marketing the region nationally and globally and serving as a connector to welcome these businesses and leaders, and the Chambers CEO Council for Growth is working in 2020 to assess infrastructure needs and identifying opportunities to support this R&D and cell and gene therapy focused growth.

The Greater Philadelphia metro area ranked in the top 10 most active regions in the U.S. for venture funding last year, with venture capital funding in health care more than doubling over the past four years. Recent acquisitions and funding wins speak to the momentum, and we can certainly expect investment growth to continue in 2020.

The region is home to nearly 100 colleges and universities. Through efforts such as the Chambers Regional College and University Presidents Alliance, comprised of higher education leaders focusing on opportunities for collaboration and advocacy, attracting talent to these institutions and retaining talent in our region will continue. The regions robust and growing ecosystem of laboratories, start-ups, manufacturing, and health care technology companies will create more job opportunities which will drive even higher graduate retention.

Connected health technology, through innovative partnerships like our work with Comcast on Quil, is another area in which our region is creating breakthroughs, as technology gives patients new tools and experiences to manage their care. We can expect new developments in this quick-moving industry.

Daniel J. Hilferty is chairman of the Chamber of Commerce for Greater Philadelphia chief executive officer of Independence Health Group, parent of Independence Blue Cross.

Excerpt from:
5 Predictions for Philadelphia's Cell and Gene Therapy Sector in 2020 - Philadelphia magazine

"Unhealthy" Gut Microbiome Linked to PCOS and Obesity in Teens – Technology Networks

Teens with obesity and polycystic ovary syndrome (PCOS) have more unhealthy gut bacteria, suggesting the microbiome may play a role in the disorder, according to new research published in the Endocrine Societys Journal of Clinical Endocrinology & Metabolism.PCOS is complicated endocrine disorder affecting 6 percent to 18 percent of women of reproductive age and work in adult women indicates that changes in bacteria be involved. The hormone disorder is characterized by elevated testosterone levels in the blood that cause acne, excess hair growth and irregular periods. Teens with PCOS often also struggle with obesity and have a higher risk for type 2 diabetes, infertility, and depression.

We found that in adolescents with PCOS and obesity, the bacterial profile (microbiome) from stool has more unhealthy bacteria compared to teens without PCOS, said the studys corresponding author, Melanie Cree Green, M.D., Ph.D., of Childrens Hospital Colorado in Aurora, Colo. The unhealthy bacteria related to higher testosterone concentrations and markers of metabolic complications.

The researchers studied 58 teens with obesity and found that girls with PCOS have an altered gut microbiome compared to those without the condition. These girls had more unhealthy bacteria in their stool which was related to higher testosterone levels and other markers of metabolic syndrome, such as higher blood pressure, liver inflammation and plasma triglycerides.

The gut microbiome may play a role in PCOS and its related metabolic complications, and these changes can be found in teenagers who are early in the course of the condition, Green said.ReferenceJobira et al. (2020) Obese adolescents with PCOS have altered biodiversity and relative abundance in gastrointestinal microbiota. Journal of Clinical Endocrinology & Metabolism. DOI: https://doi.org/10.1210/clinem/dgz263

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:
"Unhealthy" Gut Microbiome Linked to PCOS and Obesity in Teens - Technology Networks

Weekly pick of brain tumour research news from around the world – Brain Tumour Research

The first symposium of the South West Brain Tumour Centre was held on Thursday at Derriford Hospital in Plymouth. During a fascinating and very well attended event, topics covered included the mechanism of tumour development, new drug targets, new biomarkers and brain tumour imaging. The South West Brain Tumour centre is of course one of the UK Centres of Excellence funded by Brain Tumour Research.

A really big cancer wide story this week is here Immune discovery 'may treat all cancer' applicable to some solid tumours but not yet brain it really shows the direction of travel toward immunotherapy I have recommended this book before but if interested please do read The Breakthrough by Charles Graeber it is available on Amazon and you can read reviews here - http://www.charlesgraeber.com.Researchers uncover novel drug target for glioblastoma by revealing a cellular pathway that appears to contribute to glioma stem cell spread and proliferation. This pathway shows that glioma stem cells ability to access key nutrients in their surrounding microenvironment is integral for their maintenance and spread. Finding a way to interrupt this feedback loop will be important for treating glioblastoma.

An intelligent molecule could significantly extend the lives of patients with glioblastoma, research finds. The molecule, called ZR2002, which can be administered orally and is capable of penetrating the blood-brain barrier, could delay the multiplication of glioblastoma stem cells resistant to standard treatment. According to scientists in the Metabolic Disorders and Complications Program at the Research Institute of the McGill University Health Centre (RI-MUHC) the ZR2002 molecule is designed to kill two birds with one stone: on top of attacking the tumour, it destroys its defence system.

Researchers find clues to drug resistance in medulloblastoma subtype.US scientists have identified specific types of cells that cause targeted treatment to fail in a subtype of medulloblastoma. They found while the majority of cells responded to treatment, diverse populations within the tumour continue to grow leadingto treatment resistance. They concluded that the diversity of cells within tumours allow them to become rapidly resistant to precisely targeted treatments," and that due to this tumour cell diversity, molecularly precise therapies should be used in combinations to be effective."

Nanoparticles deliver 'suicide gene' therapy to paediatric brain tumours growing in mice So-called "suicide genes" have been studied and used in cancer treatments for more than 25 years. Researchers report here that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a ''suicide gene'' to paediatric brain tumour cells implanted in the brains of mice.

According to a study that uncovers an unexpected connection between gliomas and neurodegenerative diseases a protein typically associated with neurodegenerative diseases like Alzheimers might help scientists explore how gliomas become so aggressive. The new study, in mouse models and human brain tumour tissues, was published in Science Translational Medicine and found a significant expression of the protein TAU in glioma cells, especially in those patients with better prognoses. Patients with glioma are given a better prognosis when their tumour expresses a mutation in a gene called isocitrate dehydrogenase 1 (IDH1). In this international collaborative study led by the Instituto de Salud Carlos III-UFIEC in Madrid, Spain, those IDHI mutations stimulated the expression of TAU. Then, the presence of TAU acted as a brake for the formation of new blood vessels, which are necessary for the aggressive behaviour of the tumours.

'Innovative research award' helps Colorado scientists block brain cancer escape routes Cancers used to be defined by where they grow in the body - lung cancer, skin cancer, brain cancer, etc. But work in recent decades has shown that cancers sharing specific genetic changes may have more in common than cancers that happen to grow in an area of the body. For example, lung cancers, skin cancers, and brain cancers may all be caused by mutation in a gene called BRAF. Drugs targeting BRAF have changed the treatment landscape for melanoma, an aggressive form of skin cancer, and are also in use against lung cancers and brain cancers with BRAF mutations. It is really worth clicking through to read more on this and the ultimate goal of identifying new potential targets for combination therapy and new agents that could be added to BRAF inhibiting drugs in brain cancer to keep the cancer from developing resistance.

Related reading:

If you found this story interesting or helpful,sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

Go here to read the rest:
Weekly pick of brain tumour research news from around the world - Brain Tumour Research

Global Cancer Therapies Industry – Yahoo Finance

The global market for Cancer Therapies is projected to reach US$220. 5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the disease.

New York, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Therapies Industry" - https://www.reportlinker.com/p05817674/?utm_source=GNW Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities. - Against the backdrop of tumor diversity, the universal "one size fits all" therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancers diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancers mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called "alternative splicing. Aberrations in alternative splicing are linked to cancers progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancers biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide. - Competitors identified in this market include, among others, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company , F. Hoffmann-La Roche Ltd., Glaxosmithkline Plc, Johnson & Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc.,Takeda Pharmaceutical Company Limited.

Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

CANCER THERAPIES MCP-1MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Cancer Therapies: An Outlook Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market By Cancer Type USA Leads the Cancer Therapies Market Biotherapies to Drive Growth Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth Total Number of New Cancer Cases by Type: 2018 Total Number of Cancer Deaths by Type: 2018 Cancer Incidence by Region: 2018 Cancer Mortality by Region: 2018 Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018 Cancer Research Spending Continues to Witness Growth Number of FDA-Approved Cancer Drugs: 2010-2018 Select Cancer Drug Approvals in 2019 Select Cancer Drug Approvals in 2018 Cancer Drug Pipeline to Change the Pharma Landscape Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019 Global Competitor Market Shares Cancer Therapies Competitor Market Share Scenario Worldwide (in %): 2019 Select Leading Cancer Drugs Worldwide by Sales: 2018

2. FOCUS ON SELECT PLAYERS AbbVie, Inc. (USA) Amgen, Inc. (USA) Astellas Pharma, Inc. (Japan) AstraZeneca Plc. (UK) Bayer AG (Germany) Bristol-Myers Squibb Company (USA) Select Late Stage Compounds in Bristol-Myers Squibb Companys Oncology Pipeline (As of 2019) Celgene Corporation (USA) Eli Lilly and Company (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Glaxosmithkline Plc (UK) Johnson & Johnson Services, Inc. (USA) Merck KGaA (Germany) Novartis AG (Switzerland) Pfizer, Inc. (USA) Takeda Pharmaceutical Company Limited (Japan)

3. MARKET TRENDS & DRIVERS Industry Focuses on New Approaches to Treat Cancer Recent Advancements in Cancer Drug Discovery A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team Lymphoma Therapy Developed by BeiGene Secures US FDA Approval New Linker Technology for Enhancing Stability of ADCs Personalized Medicine Gains Importance Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care North American Companion Diagnostics Market (2019) European Companion Diagnostics Market by Disease Area (2019) Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs Combination Therapy: A Double Whammy Success Patent Expiries of Branded Drugs to Trigger Generic Competition Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer Development of Novel Drug Candidates and Potential Therapies Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies Rise in Patient Assistance Programs (PAPs) Top Financial Concerns for Cancer Patients: Ranked In Order of Influence Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses Growth Drivers and Restraints Demographics & Lifestyles Raise the Risk of Cancer Percentage Breakdown of New Cases for All Cancers by Gender (2019) Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019) Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019) Unmet Needs Leave Scope for Further Research and Development Low Entry Barriers in Cancer Research Encourages Breakthrough Developments Increasing Investments by National Health Authorities NCI Funding for Cancer Research (2002, 2008, 2014 and 2020) Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth Molecular Imaging of Cancer: Critical in Improving Patient Outcomes Innovations, Improvements, and Approvals Propel Growth Select Cancer Drug Approvals (2018 & 2019) Emerging Challenges in Cancer Drug Development Drug Failures Deter Prospects of New Therapies High Prices of Targeted Therapies Act as a Speed Breaker Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016 Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation Limited Tumor Specificity and Toxicity Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance Reduced Smoking Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018 Reimbursement Coverage Remains a Major Challenge Increase in Multidrug Resistance Stringent Regulations Delay Market Approval Challenges Encountered in Clinical Trials Overview of Cancer Therapy Segments Immunotherapy: A Promising Segment Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019 Monoclonal Antibodies for Cancer Treatment Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment Vaccines: A Promising Future Area of Cancer Therapeutics Approved Therapeutic Cancer Vaccines Worldwide CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients Immune Cells for Cancer Treatment UK Researchers New Approach Holds Potential to Boost Immunotherapies Targeted Therapy: An Overview Types of Targeted Therapy Chemotherapy: An Overview Types of Chemotherapy Risks Associated with Chemotherapy Hormone Therapy Drug Classes in Hormone Therapy Cancer Types, Approved and Pipeline Drugs Prostate Cancer Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018 Select General Risk Factors and their Relative Risk Rate in Prostate Cancer Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC) Prostate Cancer Phase IV Completed Clinical Trials with Results Lung Cancer Age-Standardized Lung Cancer Rates for Select Countries Age-Standardized Lung Cancer Rates in Men for Select Countries Age-Standardized Lung Cancer Rates in Women for Select Countries Select FDA-Approved Non-Small Cell Lung Cancer Drugs Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019 Select Phase III Completed Clinical Trials with Results: As of December 30, 2019 Breast Cancer Select FDA Approved Breast Cancer Drugs Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Renal Cancer Select FDA-Approved Renal Cell Carcinoma Drugs Cervical Cancer Colorectal Cancer Select FDA-Approved Colorectal Cancer Drugs Skin Cancer Skin Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Pancreatic Cancer Non-Hodgkins Lymphoma Leukemia Standard Approved Mode of Therapy for AML by Age Group Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Bladder Cancer Endometrial Cancer

4. GLOBAL MARKET PERSPECTIVE Table 1: Cancer Therapies Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 2: Cancer Therapies Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 Table 3: Cancer Therapies Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Chemotherapy (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 5: Chemotherapy (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 6: Chemotherapy (Treatment Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Targeted Therapy (Treatment Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 8: Targeted Therapy (Treatment Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 9: Targeted Therapy (Treatment Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Immunotherapy (Treatment Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 11: Immunotherapy (Treatment Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 12: Immunotherapy (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 13: Hormonal Therapy (Treatment Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2to 2025 Table 14: Hormonal Therapy (Treatment Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 15: Hormonal Therapy (Treatment Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 16: Other Treatment Types (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 17: Other Treatment Types (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 18: Other Treatment Types (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 19: Blood Cancer (Cancer Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 Table 20: Blood Cancer (Cancer Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 21: Blood Cancer (Cancer Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 Table 22: Breast Cancer (Cancer Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 Table 23: Breast Cancer (Cancer Type) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 Table 24: Breast Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 25: Prostate Cancer (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 26: Prostate Cancer (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 27: Prostate Cancer (Cancer Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 28: Gastrointestinal Cancer (Cancer Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 29: Gastrointestinal Cancer (Cancer Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 30: Gastrointestinal Cancer (Cancer Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 31: Gynecologic Cancer (Cancer Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 32: Gynecologic Cancer (Cancer Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 33: Gynecologic Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 34: Lung Cancer (Cancer Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 Table 35: Lung Cancer (Cancer Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 36: Lung Cancer (Cancer Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 37: Other Cancer Types (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 38: Other Cancer Types (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 39: Other Cancer Types (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Overview Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market Estimated Number of New Cancer Cases and Deaths in the US (2019) Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018 Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent Personalized Medicine Gathers Momentum for Cancer Treatment in the US A Surging US Prostate Cancer Therapeutics Market Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care CMS Hikes Reimbursement Rate for CAR-T Therapy Market Analytics Table 40: United States Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 41: Cancer Therapies Market in the United States by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 42: United States Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 43: United States Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 44: Cancer Therapies Market in the United States by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 45: United States Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 CANADA Number of New Cancer Cases in Canada: 2019 Market Analytics Table 46: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 47: Canadian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 48: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 49: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 50: Canadian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 51: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 JAPAN Table 52: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 53: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 54: Japanese Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 55: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 56: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 57: Japanese Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 CHINA Cancer Therapies Market: Overview Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products Market Analytics Table 58: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 59: Cancer Therapies Historic Market Analysis in China in US$ Million by Treatment Type: 2009-2017 Table 60: Chinese Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 61: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 62: Cancer Therapies Historic Market Analysis in China in US$ Million by Cancer Type: 2009-2017 Table 63: Chinese Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 EUROPE Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018 Market Analytics Table 64: European Cancer Therapies Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 65: Cancer Therapies Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 Table 66: European Cancer Therapies Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 68: Cancer Therapies Market in Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 69: European Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 70: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 71: Cancer Therapies Market in Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 72: European Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 FRANCE Table 73: Cancer Therapies Market in France by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 74: French Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 75: French Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 76: Cancer Therapies Market in France by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 77: French Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 78: French Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 GERMANY Table 79: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 80: German Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 81: German Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 82: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 83: German Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 84: German Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ITALY Table 85: Italian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 86: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Treatment Type: 2009-2017 Table 87: Italian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 88: Italian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 89: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Cancer Type: 2009-2017 Table 90: Italian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED KINGDOM Table 91: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 92: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 93: United Kingdom Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 94: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 95: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 96: United Kingdom Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 SPAIN Table 97: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 98: Spanish Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 99: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 100: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 101: Spanish Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 102: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 RUSSIA Table 103: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 104: Cancer Therapies Market in Russia by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 105: Russian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 106: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 107: Cancer Therapies Market in Russia by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 108: Russian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF EUROPE Table 109: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 110: Cancer Therapies Market in Rest of Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 111: Rest of Europe Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 112: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 113: Cancer Therapies Market in Rest of Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 114: Rest of Europe Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ASIA-PACIFIC An Insight into Asia-Pacific Market for Cancer Therapies Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019 Market Analytics Table 115: Asia-Pacific Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 116: Cancer Therapies Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 Table 117: Asia-Pacific Cancer Therapies Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 118: Cancer Therapies Market in Asia-Pacific by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 119: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 120: Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 121: Cancer Therapies Market in Asia-Pacific by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 122: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 123: Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 AUSTRALIA Table 124: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 125: Australian Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 126: Australian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 127: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 128: Australian Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 129: Australian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 INDIA Table 130: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 131: Indian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 132: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 133: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 134: Indian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 135: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 SOUTH KOREA Table 136: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 137: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 138: Cancer Therapies Market Share Distribution in South Korea by Treatment Type: 2009 VS 2019 VS 2025 Table 139: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 140: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 141: Cancer Therapies Market Share Distribution in South Korea by Cancer Type: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 142: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 143: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 144: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 145: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 146: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 147: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 LATIN AMERICA Table 148: Latin American Cancer Therapies Market Trends by Region/Country in US$ Million: 2018-2025 Table 149: Cancer Therapies Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 Table 150: Latin American Cancer Therapies Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 151: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 152: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Treatment Type: 2009-2017 Table 153: Latin American Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 154: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 155: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Cancer Type: 2009-2017 Table 156: Latin American Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 ARGENTINA Table 157: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 158: Cancer Therapies Market in Argentina in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 159: Argentinean Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 160: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 161: Cancer Therapies Market in Argentina in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 162: Argentinean Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 BRAZIL Table 163: Cancer Therapies Market in Brazil by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 164: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 165: Brazilian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 166: Cancer Therapies Market in Brazil by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 167: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 168: Brazilian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 MEXICO Table 169: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 170: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 171: Mexican Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 172: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 173: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 174: Mexican Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 175: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 176: Cancer Therapies Market in Rest of Latin America by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 177: Rest of Latin America Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 178: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2to 2025 Table 179: Cancer Therapies Market in Rest of Latin America by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 180: Rest of Latin America Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 MIDDLE EAST Table 181: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 182: Cancer Therapies Market in the Middle East by Region/Country in US$ Million: 2009-2017 Table 183: The Middle East Cancer Therapies Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 184: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 185: The Middle East Cancer Therapies Historic Market by Treatment Type in US$ Million: 2009-2017 Table 186: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 187: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 188: The Middle East Cancer Therapies Historic Market by Cancer Type in US$ Million: 2009-2017 Table 189: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 IRAN Table 190: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 191: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 192: Iranian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 193: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 194: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 195: Iranian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 ISRAEL Table 196: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 197: Cancer Therapies Market in Israel in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 198: Israeli Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 199: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 200: Cancer Therapies Market in Israel in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 201: Israeli Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 202: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 203: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Treatment Type: 2009-2017 Table 204: Saudi Arabian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 205: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 206: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Cancer Type: 2009-2017 Table 207: Saudi Arabian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED ARAB EMIRATES Table 208: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 209: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 210: Cancer Therapies Market Share Distribution in United Arab Emirates by Treatment Type: 2009 VS 2019 VS 2025 Table 211: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 212: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 213: Cancer Therapies Market Share Distribution in United Arab Emirates by Cancer Type: 2009 VS 2019 VS 2025 REST OF MIDDLE EAST Table 214: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 215: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 216: Rest of Middle East Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 217: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 218: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 219: Rest of Middle East Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 AFRICA Table 220: African Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 221: Cancer Therapies Market in Africa by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 222: African Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 223: African Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 224: Cancer Therapies Market in Africa by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 225: African Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled : 75 (including Divisions/Subsidiaries - 80) Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read the original:
Global Cancer Therapies Industry - Yahoo Finance

Global Beauty and Personal Care Product Market is Expected to Reach USD 756.63 Billion by 2026 : Fior Markets – GlobeNewswire

Newark, NJ, Jan. 24, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal beauty and personal care products market is expected to grow from USD 493.34 billion in 2018 to USD 756.63 billion by 2026, at a CAGR of 5.81% during the forecast period 2019-2026.

Beauty and personal care products are used to enhance the appearance of the face or fragrance and texture of the body. Many beauty products are designed for applying to the face and body. They are generally mixtures of chemical compounds derived from natural sources or maybe synthetic or artificial. Nowadays, many companies are producing natural and organic beauty and personal care products, with the increasing consumer concern over chemical usage in beauty products. In addition to this, an increasing trend of personalization and customization of beauty and personal care products is expected to offer considerable opportunities in the market. Moreover, innovation in packaging of beauty products is further boosting the growth of the market, during the forecast period 20192026.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/407144/request-sample

Global Beauty and Personal Care Product Market Key Findings:

Browse full report with TOC athttps://www.fiormarkets.com/report/beauty-and-personal-care-products-market-by-product-407144.html

About the report:

The global beauty and personal care product market is analysed on the basis of value (USD Billion). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution and marketing channels analysis.

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To Know More Market Research Reports and Industry Analysis, Visit our Associate Website: https://marketandresearch.bizRelated Reports

Global Breast Cancer Liquid Biopsy Market - https://www.fiormarkets.com/report/global-breast-cancer-liquid-biopsy-market-by-circulating-376049.htmlGlobal Cell Therapy Technologies Market - https://www.fiormarkets.com/report/global-cell-therapy-technologies-market-by-product-consumables-376050.htmlGlobal Gene Therapy Market - https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.htmlGlobal Health Intelligent Virtual Assistant Market - https://www.fiormarkets.com/report/global-health-intelligent-virtual-assistant-market-by-products-376053.html

More:
Global Beauty and Personal Care Product Market is Expected to Reach USD 756.63 Billion by 2026 : Fior Markets - GlobeNewswire

The Center for Breakthrough Medicines is Building the World’s Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO)…

KING OF PRUSSIA, Pa., Jan. 22, 2020 /PRNewswire/--The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a Contract Development and Manufacturing Organization (CDMO) and specialty investment company, to alleviate the critical lack of capacity that is preventing patients from accessing critically needed cell and gene therapies. The CDMO is occupying over 40 percent of The Discovery Labs' 1.6 million square foot biotech, healthcare and life sciences campus in King of Prussia, PA.

The CDMO provides preclinical through commercial manufacturing of cell and gene therapies and component raw materials. It offers process development, plasmid DNA,viral vectors, cell banking, cell processing, and support testing capabilities all under one roof. The immense $1.1 billion facility will provide instant capacity as the largest known single source for accelerating the delivery and affordability of lifesaving and life-changing therapies from the bench to the patient's bedside.

The Company has initiated a substantial hiring effort targeting the best and brightest of the life sciences community including, experts in CGMP manufacturing. The Company expects to hire over 2,000 team members within the next 30 months.

The CDMO has retained Nucleus Careers, a cloud-based specialty life sciences human capital recruiting and retention management expert, to buildout the entire team. Nucleus has proprietary recruiting and retention software designed for large scale human capital buildouts of high growth companies.

In addition to developing the world's largest single-point cell and gene therapy manufacturing facility, The Discovery Labs is establishing THE COLONY which will provide custom built discovery labs, breakthrough funding, sponsored research agreements, housing and relocation for the world's leading iconic experts in cell and gene therapy.

THE COLONY will seek to work hand in hand with scientists from both academic and pharmaceutical institutions to unlock and expedite groundbreaking therapies.

Marco A. Chacn, Ph.D., Founder of Paragon Bioservices and Chairman of The Discovery Labs states, "musicians, artists, members of religious communities and great thinkers throughout time have formed colonies where freedom of thought and expression combined with unlimited dreams and potential have resulted in the world's greatest accomplishments." Dr. Chacn went on to say, "the goal of THE COLONY is to unshackle the potential of the world's greatest scientific minds."

The ability for the industry's greatest scientists to cohabitate, collaborate, cooperate, and communicate via technology and in person will create an exponential therapeutic "X FACTOR." THE COLONY seeks to unlock institutional barriers prohibiting the world's greatest scientists from moving at a pace necessary in today's ever-changing therapeutic revolution. THE COLONY will partner with the institutions where the scientists currently work by providing equity, license fees, and revenue sharing.

"The Center for Breakthrough Medicines will be serving companies from the earliest stages through commercialization. Its exceptional scale and offering will quickly relieve the production bottleneck for advanced therapies by reducing the time, complexity, and cost of commercializing vitally needed gene and cell therapies," noted Audrey Greenberg, Board Member and Executive Managing Director for The Discovery Labs.

The addition of this end-to-end manufacturing capability is expected to significantly enhance the offerings of The Discovery Labs in an area that has become one of the largest life sciences hubs in the world. Renovations are underway to construct a total of 86 plasmid, viral vector production, universal cell processing, CGMP testing, process development and cell banking suites. The viral vector and cell processing suites will be fully compliant with both U.S. Food and Drug Administration and European Medicines Agency standards. All suites will offer the flexibility to meet client-specific workflows and will be able to adapt quickly to meet demand. The Company is in the process of reserving capacity now for late 2020.

"Today brilliant scientists are advancing an unprecedented number of gene and cell therapy drug candidates. The real tragedy, however, is a scarcity of manufacturing know-how, which is complex and expensive," said Alex Karnal, Partner and Managing Director of Deerfield Management and a Board Member of the Discovery Labs. "With its visionary business model, it is hoped that The Center for Breakthrough Medicines will help realize the promise of cell and gene therapies in time to treat the many patients who need them."

The Discovery Labs provides a central campus where the world's greatest scientists can collaborate on new therapeutic discoveries to eradicate diseases affecting small and large segments of the global population. The Center for Breakthrough Medicines will work with these leaders, life sciences companies, large pharmaceutical companies, and academic and government institutions.

This new manufacturing capability is a transformational addition to The Discovery Labs market offering and dovetails with The Discovery Labs biotech incubator, Unite IQ. Unite IQ offers immediate space to emerging life sciences companies and scientists giving them the ability to grow from startup to enterprise company on one campus. The incubator and accelerator space at Unite IQ provides a comprehensive home for startups with every resource needed to initiate business operations. Unite IQ tenants are expected to utilize the discovery, development, testing, and manufacturing capabilities of the Center for Breakthrough Medicines with seamless forward integration of processes and analytics, and seamless tech transfer from research lab to large scale production

The Emerging Field of Cell and Gene Therapy in Pennsylvania

The demand for clinical and commercial manufacturing capacity is acute and expected to remain that way. The current shortfall in manufacturing for cell and gene therapies is severely underserved with few approved products. There are currently approximately 1,100 advanced therapies in the pipeline pending FDA approval. This will greatly increase highly skilled manufacturing demand. Dr. Peter Marks, Director of the FDA Center for Biologics Evaluation and Research, states, "what keeps me up at night is will we be able to manufacture these on a scale that will allow us to bring the benefit of these therapies to patients?"He further added that "if we can help see cost of goods and ability to manufacture reproducibly improve, I think that'll be a big thing."All of this adds up to a supply constrained market that The Center for Breakthrough Medicines aims to help address.

With the potential to treat and even cure disabling, and deadly diseases, gene and cell therapies are ushering in a new era of medicine. These therapies may eventually be able to cure genetic conditions, such as cystic fibrosis, hemophilia A, and a range of cancers. The Philadelphia area has become the epicenter for the flourishing field of gene and cell therapy. Research from CBRE currently ranks the market among the top biotech clusters for medical research and health services. The cluster has become known worldwide as "Cellicon Valley"for its leadership in research and development of this rapidly evolving field. The Discovery Lab's suburban Philadelphia location offers a talent rich environment due to the area's preponderance of large pharmaceutical companies and the Philadelphia region's position boasting the top 10 universities and primary school systems in nation.

Over the past three years, multiple Philadelphia companies have received approvals for major breakthroughs in cell and gene therapy. In 2017, the U.S. FDA approved the first-ever CAR-T cell therapy, Novartis's Kymriah, which originated at the University of Pennsylvania. Shortly thereafter, the FDA gave landmark approval for the first-ever gene therapy to treat a genetic blindness condition to Spark Therapeutics, a start-up founded by researchers at Children's Hospital of Philadelphia. These discoveries and others in the pipeline are attracting billions of dollars of venture capital. The Greater Philadelphia Region set a recent record in venture capital financing.

The Discovery Labs Center for Breakthrough Medicines joins more than 25 healthcare, life sciences and tech-enabled companies that already call The Discovery Labs King of Prussia home.

Brian O'Neill, Founder of The Discovery Labs Center for Breakthrough Medicines, and Tony Khoury, Board Member of The Discovery Labs and Engineer at Project Pharma, will be speaking at the 2020 PhacilitateWorld Stem Cell Summit discussing The Future of Gene Therapy Manufacturing at 4 p.m. today at the Hyatt Regency in Miami, Florida.

Contact Audrey Greenberg at agreenberg@thediscoverylabs.com for more information about development services, manufacturing capacity, incubator space or leasing information at the property.

About The Discovery LabsPart of MLP Ventures, The Discovery Labs is a global provider of world-class cGMP manufacturing, turnkey laboratory solutions, critical materials and office space that support therapeutic products and services to the biotechnology and pharmaceutical industry so that groundbreaking medicines get to the patients that need them. The location in eastern King of Prussia is a prototype for a global rollout of The Discovery Labs, providing Big Pharma, emerging life sciences, consumer and technology companies flexible, end-to-end technical real estate and business infrastructure for the customer's entire lifecycle from discovery to delivery, including manufacturing capacity. It is the first fully integrated environment that merges technology and life sciences under one roof to drive innovation.

About Deerfield Management

Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.

Media Contact:Tony DeFazio, DeFazio Communications(o) 484-534-3306 (c) 484-410-1354tony@defaziocommunications.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/the-center-for-breakthrough-medicines-is-building-the-worlds-largest-cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-to-launch-in-king-of-prussia-pa-300991566.html

SOURCE The Discovery Labs

Read more here:
The Center for Breakthrough Medicines is Building the World's Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO)...

Gene Therapy Market Worth $13.0 Billion by 2024 – Exclusive Report by MarketsandMarkets – Yahoo Finance

CHICAGO, Jan. 20, 2020 /PRNewswire/ -- According to the new market research report "Gene Therapy Marketby Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024", published by MarketsandMarkets, is projected to reach USD 13.0 billion by 2024 from USD 3.8 billion in 2019, at a CAGR of 27.8% from 2019 to 2024.

MarketsandMarkets_Logo

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of the market.

The non-viral vectors segment accounted for the largest share of the market, by vector, in 2018

The Gene Therapy Market, by vector, has been segmented into viral and non-viral vectors. Non-viral vectors accounted for the largest share of the market in 2018. This is mainly attributed to the high market penetration of oligonucleotide-based non-viral vector gene therapies.

Browsein-depth TOC on "Gene Therapy Market" 127 - Tables25 - Figures 129 - Pages

The demand for gene therapies for the treatment of cancer is expected to grow at a high rate

Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. However, the cancer segment is estimated to grow at the highest CAGR during the forecast period owing to the increasing incidence of cancer and the rising demand for CAR T-cell therapies.

Get 10% Customization Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122857962

North America is the largest regional market for gene therapy products

The global Gene Therapy Market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the market, followed by Europe. Moreover, the North American market is estimated to register the highest growth rate during the forecast period. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

The prominent players operating in the Gene Therapy Market include Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Itlay), Orchard Therapeutics plc. (UK), Sibiono GeneTech Co. Ltd. (China), Alnylam Pharmaceuticals, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Dynavax Technologies (US), Jazz Pharmaceuticals, Inc. (Ireland), and Akcea Therapeutics (US).

Browse Adjacent Markets @Biotechnology MarketResearch Reports & Consulting

Get Special Pricing on Bundle Reports:https://www.marketsandmarkets.com/RequestBundleReport.asp?id=122857962

Browse Related Reports:

Regenerative Medicine Marketby Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024

Story continues

Viral Vector Manufacturing Marketby Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023

About MarketsandMarkets:

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Shelly SinghMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA : +1-888-600-6441Email: sales@marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/gene-therapy.asp Research Insight:https://www.marketsandmarkets.com/ResearchInsight/gene-therapy-market.asp Visit Our Website:https://www.marketsandmarkets.com

View original content:http://www.prnewswire.com/news-releases/gene-therapy-market-worth-13-0-billion-by-2024---exclusive-report-by-marketsandmarkets-300989478.html

SOURCE MarketsandMarkets

Read more from the original source:
Gene Therapy Market Worth $13.0 Billion by 2024 - Exclusive Report by MarketsandMarkets - Yahoo Finance

Gene Therapy Recovers Vision in Mice Models of MS, Uncovers How… – Multiple Sclerosis News Today

Early research in animal models and human samples reveals how loss of communication between nerve cells contributes to the symptoms of multiple sclerosis (MS), and shows how gene therapy could be used to preserve such connections and protect againstvision loss.

Researchers say their work identifies a new approach for developing MS therapies that target nerve cell communication, rather than myelin loss, and could be applicable to other neurodegenerative disorders.

The study, Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease, was published in the journal Immunity.

MS is a neurological disease marked by inflammation and a self-attack of the immune system against a persons brain, spinal cord, and optic nerves.

This attack damages the protective fatty substance covering nerve fibers (axons), which are necessary for proper transmission of nerve signals called myelin. As the myelin sheath is lost (demyelination), the communication between nerve cells is damaged or even interrupted, and nerve cell death occurs, leading to a range of disease symptoms.

Some MS patients experience a version of the disease called progressive MS, in which symptoms continuously worsen over time while their central nervous system (brain and spinal cord) shrinks (atrophies), and the junctions at which nerve cell terminals meet to communicate with each other, called synapses, are lost.

The majority of MS medications work to inhibit the self-attacking immune responses and inflammatory demyelination, but the neurodegenerative aspects of the disease have been more difficult to stop, particularly for patients with progressive MS.

Most MS research and FDA-approved treatments focus on demyelination and axon death, Dorothy P. Schafer, PhD, professor at the University of Massachusetts Medical School, said in a press release.

Far less is known about what happens to the synaptic connections between neurons, which has proven to be a key aspect of neurodegeneration likely leading to cognitive decline in other diseases such as Alzheimers disease, Schafer said.

Using tissue samples from deceased MS patients, a primate model of MS, and mice models of demyelinating disease, Schafer and colleagues investigated how synapses change during MS.They specifically looked at synapses involved in transmitting visual information from the eye to the brain via the optic nerve.

According to the studys first author, Sebastian Werneburg, PhD, a postdoctoral researcher at Schafers lab, the visual system is an ideal model for investigating MS because its easy to access for therapeutic intervention, subtle changes can be readily detected, and the visional pathway is affected in almost half of all patients with the disease.

Most MS patients experience vision problems at some point, which result from damage to the optic nerve or from lack of coordination in the eye muscle. These problems can be the first indication of the disease.

Similar to other neurodegenerative diseases, researchers found a profound synaptic loss in patient samples as a consequence of immune cells called microgliaeating nerve cell connections.

Microglia are cells that serve as one of the first and main forms of immune defense in the central nervous system, acting to clear cellular debris and dead neurons via phagocytosis a process by which some cells engulf other cells or particles.

In mice, synapse loss occurred independently of local demyelination and neuronal degeneration, but coincided with a rise in a specific immune factor called C3. C3 is part of the complement system, and is normally not present in the brains of adults. It is produced and activated during demyelinating diseases, but it is not clear why.

As C3 was seen to bind to synapses in models of MS, researchers reasoned this complement protein might be involved with the ongoing destruction of synapses in mice with MS-like disease.

To test this hypothesis, they specifically neutralized C3 at synapses of the visual pathway using gene therapy in mice. The strategy basically worked by delivering genetic material to synapses that provided instructions for the production of a C3 inhibitor.

After injection of the therapy, the inhibitor successfully blocked C3, reduced microglia engulfment, and preserved nerve cell connections, which improved eyesight in mice.

As a result of this inhibition, we saw improved visional function in mice, Werneburg said.

Overall, based on the results, the team believes that C3 probably is sending a signal to microglia telling them to eliminate synapses.

The next step will be to determine how C3 turns active during MS and other neurodegenerative diseases.

Its possible that therapies targeting different circuits of the brain can be used to protect against synaptic damage in other neurodegenerative diseases such as Alzheimers, Schafer said.

Ana is a molecular biologist with a passion for discovery and communication. As a science writer she looks for connecting the public, in particular patient and healthcare communities, with clear and quality information about the latest medical advances. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in genetics, molecular biology, and infectious diseases

Total Posts: 1,053

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Originally posted here:
Gene Therapy Recovers Vision in Mice Models of MS, Uncovers How... - Multiple Sclerosis News Today

Gene Therapy Protects Eyesight in Models of Multiple Sclerosis – Technology Networks

New research by Dorothy P. Schafer, PhD, at the University of Massachusetts Medical School, reveals the molecular process in which synaptic connections in the brain are damaged in multiple sclerosis and how this contributes to neurodegenerative symptoms. The paper, published in Immunity, also shows how gene therapy may be used to preserve neural circuits and protect against vision loss in the disease.

These findings suggest a path for developing therapies that may protect synapses from the damaging effects of MS and could be broadly applicable to other neurodegenerative disorders, according to Dr. Schafer, assistant professor of neurobiology, and Sebastian Werneburg, PhD, a postdoctoral fellow in the Schafer lab.

"Most MS research and FDA-approved treatments focus on demyelination and axon death," said Schafer. "Far less is known about what happens to the synaptic connections between neurons, which has proven to be a key aspect of neurodegeneration likely leading to cognitive decline in other diseases such as Alzheimer's disease."

Multiple sclerosis is a neurological disease of the central nervous system affecting more than 2 million people worldwide. The disease involves an abnormal response of the body's peripheral immune system against the brain, spinal cord and optic nerves, which damages the fatty substance surrounding nerve fibers called myelin. Recurrent episodes of inflammation result in demyelination. As the myelin is stripped away, the nerve fibers are exposed to inflammatory attacks from the immune system and the transmission of nerve signals within the central nervous system are altered or stopped completely. A small subset of MS patients experience chronic progressive neurodegenerative symptoms accompanied by significant synaptic loss and central nervous system atrophy. This version of the disease is called progressive MS.

FDA-approved medications for treating MS have been developed to limit and reduce the number of relapses, which delay progression of the disease and minimize demyelination, but there is no cure for the disease and patients are still left with disability. Current therapies work to inhibit peripheral immune attack of the central nervous system and inflammatory demyelination, but the neurodegenerative aspects of the disease have proven harder to decelerate, particularly for patients with progressive MS.

Vison loss is one of the most common symptoms of MS and is often one of the first that patients notice. Problems with vision result from damage to the optic nerve that connects the eye to the brain or from lack of coordination in the eye muscle.

"The retinogeniculate system, which comprises neurons that extend their axons via the optic nerve to the thalamus in the brain, is an ideal model for investigating MS because it's easy to access for therapeutic intervention, subtle changes can be readily detected and the visional pathway is affected in almost half of all patients with the disease," said Dr. Werneburg.

Profound synaptic loss was observed in animal models as microglia engulfed and eliminated presynaptic connections. Microglia are the immune cells of the central nervous system and are emerging as key players in regulating neural circuit structure in health and disease. One of the vast number of functions microglia perform in the brain is similar to the role macrophages perform in the immune system: clearing cellular decay and dead neurons from tissue.

"We found the protein C3 in abundance at synapses," said Werneburg.

C3 is not normally found in adult brain tissue. C3 protein usually only shows up in neural tissue during the developmental stages of the brain when synapses are being pruned. Synaptic pruning eliminates weak or unused synapsis as the brain matures to help efficiency and conserve energy.

In the case of demyelinating disease, it is not known why C3 is being produced and activated. This complement protein binds to synapses, sending the signal to microglia that the otherwise healthy-seeming synapse should be eliminated. This leads microglia to attack synapses.

Schafer, in collaboration with Guangping Gao, PhD, the Penelope Booth Rockwell Professor in Biomedical Research, professor of microbiology & physiological systems, director of the UMMS Horae Gene Therapy Center and Viral Vector Core, and co-director of the Li Weibo Institute of Rare Disease, used a gene therapy approach and adeno-associated virus to deliver Crry, an inhibitor of C3, specifically to synapses in the visual system while leaving the rest of the brain untouched, to see if synapses could be spared and vision preserved. Crry is a natural inhibitor of complement proteins such as C3. These regulators help protect cells or tissue from unwanted attack by the immune system.

After injection of the AAV into the circuit, Crry localized to synapses and successfully preserved them by binding to C3 so microglia couldn't damage them.

"As a result of this inhibition, we saw improved visional function in mice," said Werneburg.

Schafer said the protective effects of the AAV-delivered inhibitor were specific to the visual circuit. "It's possible that therapies targeting different circuits of the brain can be used to protect against synaptic damage in other neurodegenerative diseases such as Alzheimer's."

The next step for Schafer and colleagues will be to determine how the C3 protein is being activated and produced during MS and other neurodegenerative diseases.

Reference: Werneburg, S., Jung, J., Kunjamma, R. B., Ha, S.-K., Luciano, N. J., Willis, C. M., Gao, G., Biscola, N. P., Havton, L. A., Crocker, S. J., Popko, B., Reich, D. S., & Schafer, D. P. (2020). Targeted Complement Inhibition at Synapses Prevents Microglial Synaptic Engulfment and Synapse Loss in Demyelinating Disease. Immunity, 52(1), 167-182.e7. https://doi.org/10.1016/j.immuni.2019.12.004

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Link:
Gene Therapy Protects Eyesight in Models of Multiple Sclerosis - Technology Networks

The year in new drugs: Looking back and ahead – Oklahoman.com

Gene therapy is a very hot area. Scientists can now fix defective genetic mutations that cause diseases. An initial focus is in rare diseases with urgent clinical needs, but the future holds the possibility for significant expansion.

Another promising area is the broadening of the scope of cell therapy, which is currently being used for blood cancers, into solid tumors. If this is successful, it could transform the field of personalized cancer care.

Finally, Biogen has a novel antibody drug for the treatment of Alzheimers. If the FDA approves this therapy, it could lead to the resurgence of Alzheimers drug development, which represents a huge unmet medical need.

How about at OMRF? What did 2019 deliver, and what has you excited for 2020?

The FDA approved Adakveo in November, a new drug for sickle cell disease based on discoveries made by OMRFs Dr. Rod McEver. In 2020, Im excited about Progentec, an OMRF spin-off company thats developing novel diagnostic and disease management solutions for autoimmune patients.

Also, we have a new startup called Ambocept thats developing novel cancer therapeutics. Finally, two drugs that began in OMRF labs are progressing in clinical trials: one to treat hearing loss, the other for people suffering from deadly brain cancers.

Paula Burkes, Business writer

(Story continued below...)

More here:
The year in new drugs: Looking back and ahead - Oklahoman.com

Teenager’s experimental gene therapy treatment could change the lives of millions of sickle cell patients worldwide – Genetic Literacy Project

Meet Helen Obando, a shy 16-year-old who likes to dance when her body isnt ravaged by the debilitating symptoms of sickle cell disease. The genetic blood disorder can cause strokes, organ damage and intense pain.

After a lifetime of pain and potential permanent damage to her body, Helen had the opportunity to receive a breakthrough experimental treatment at Boston Childrens Hospital that would make her the youngest person in the U.S. to have her DNA reset in an attempt to cure her sickle cell disease.

The outcome of her gene therapy could help determine how an estimated 100,000 people in the U.S. and millions more around the world are treated. Sickle cell disease most commonly affects people from sub-Saharan Africa, and about 1 in 500 African-Americans have the blood disorder, the most commonly inherited blood disorder in the U.S. But some people with the disease have southern European, Middle Eastern or Asian backgrounds or, like Helen, are Hispanic. For decades, attention and money for research have not matched the scale of the problem.

Why has it taken so long for the scientific research community to push ahead with promising therapies for sickle cell?

Read full, original post: A Teenagers Breakthrough Gene Therapy for Sickle Cell Disease

Follow this link:
Teenager's experimental gene therapy treatment could change the lives of millions of sickle cell patients worldwide - Genetic Literacy Project

Alberta baby Mighty Hudson home after gene therapy: hes cured – Global News

The first six months of his young life have been a roller-coaster but Mighty Hudson Cowie is back home in Alberta after an experimental gene therapy procedure in Tennessee was successful.

Its been so long since weve got to see our family, our friends, Hudsons dad Ian said. Even just to be able to show him off to everybody. Weve spent the last six months seeing how amazing of a little guy he is.

Now we finally get to share that with everybody.

Hudson was diagnosed with Severe Combined Immunodeficiency (SCID) within days of his birth on June 23. The condition, known to many as Bubble Boy Disease, prevents his body from fighting illnesses. Essentially, he didnt have an immune system.

READ MORE:Hundreds attend donor drive for Mighty Hudson, Alberta baby with rare immune disease

In August, Hudson was accepted into a gene therapy program at St. Jude Childrens Research Hospital in Memphis. A medical team removed some of his bone marrow cells and replaced the faulty gene with a corrected one. The cells were placed back into his body through an IV.

Story continues below advertisement

They took his own bone marrow out in his bone marrow, hes got hematopoietic stem cells. They were able to take those cells and modify them to create a product, a repaired version of those cells, and then give them back to him, Ian told Global News on Monday.

Medicine is amazing. We took a chance on science and were so glad that we did. Its amazing what theyre able to do.

Ian and his wife Hayley were weighing two options for their little boy: using donor cells or a revamped version of Hudsons own cells. They decided on the second, which meant a trial at St. Judes.

We weighed the pros and cons of both options and for us, [and] personally, we decided that gene therapy seemed like the safer way to go, Ian said.

It didnt rely on a donor, it was the new up-and-coming medicine, the existing results for gene therapy were already incredibly promising and then, as an added bonus, it had substantially less chemotherapy requirements.

Story continues below advertisement

WATCH: (Sept. 9, 2019) A Morinville baby with a rare disorder received a life-changing procedure in the U.S. Hudson Cowies parents give Su-Ling Goh an update on therapy for his immune system.

It honestly sounded too good to be true, Hayley added.

With bone marrow transplant, we heard of graft versus host disease, where its somebody elses cells and they can reject them. With gene therapy, having his own cells, he wasnt going to reject them because his body already knows them.

A few months after the transplant, they started to see results: Hudsons first T-cells, a type of white blood cell thats a key component of the immune system.

From three months, it exploded. At four months, it was even more T-cells. The growth was exponential, Ian said.

Story continues below advertisement

I think thats the thing every doctor hopes to get to say to their patients one day: Hes cured. And the day that we left Memphis, she said that. She said: Hes cured.

We squealed like little schoolgirls. It was very exciting.

Hudsons immune system right now can be compared to that of a newborn baby.

As hes introduced to small bugs, itll just keep growing and growing and be normal, Hayley explained.

There are still unknowns, but the family is very hopeful.

He was Patient 12 on the trial and from what we were informed, everyone on the trial has done tremendously well, Ian said.

I just think its amazing, Hayley added. Its amazing that we were the first ones who got on newborn screening and that this trial was even available for us. It just seems that everything completely lined up.

Story continues below advertisement

I feel like everything has just fallen into place to get him cured.

The treatment is just amazing. Our doctors are brilliant, its just all incredible and hes doing great.

Hudson was one of the first babies to be screened for SCID through a new program. Since SCID was added in May 2019, the Alberta Health Services Newborn Metabolic Screening Program has screened over 34,000 newborns and has diagnosed four cases of SCID.

While very much welcome, being home is still a big change for the Cowies.

Im still processing, even now, Hayley said. Its nice to go see people but we were in isolation for so long that it doesnt just flip all of a sudden. I know were still really protective and we can hear a cough from miles away.

Story continues below advertisement

It was surreal to leave but I feel like Im still dreaming a little bit.

They havent attempted any big outings yet especially given its flu season but they have been able to go to some family dinners.

Its an adjustment for sure, but a good adjustment, Hayley said. He loves people Hes always just smiling and playful hes just happy.

The Cowies will be back in Tennessee for one day for a checkup this weekend. Hudson will have another checkup with the St. Judes team next month. Hell have followups at least once a year until hes 10 years old.

2020 Global News, a division of Corus Entertainment Inc.

More:
Alberta baby Mighty Hudson home after gene therapy: hes cured - Global News

UK biotech PhoreMost to work with Otsuka on gene therapy projects – – pharmaphorum

Building on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun a collaboration with Japans Otsuka working on several gene therapy projects.

Cambridge-based PhoreMost said it will use its next-generation phenotypic screening platform Siteseeker to identify novel targets for Otsukas therapeutics discovery programmes.

Novel targets identified will be further validated and characterised by Otsuka as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.

Siteseeker looks at different protein shapes to find functionally active peptides that can be targeted by new therapies.

The technology looks at the entire proteome all of the proteins expressed in a live cell environment looking for druggable targets for a chosen disease.

Financial details of the agreement were not disclosed.

Dr Chris Torrance, CEO of PhoreMost, said: This collaboration with Otsuka is further recognition of the power of the Siteseeker approach to drive the identification of novel, druggable targets.

We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.

PhoreMost was one of two UK-based companies to receive funding from the government-backed agency Innovate UK to receive funding for small molecule research.

The 1 million funding was announced in 2018, and supported PhoreMost and the immune-oncology firm NeoPhore.

The companies won the funding as part of a competition organised by Innovate UK and funded by the UKs Biomedical Catalyst.

PhoreMost is also working with Indias Centre for Chemical Biology and Therapeutics, part of the Institute for Stem Cell Science and Regenerative Medicine (inStem).

The project began in July last year and, with funding from the Indian government, aims to create chemical tools that modulate novel classes of drug targets.

InStem is researching the genetic mechanisms of potency, differentiation and proliferation in human pluripotent cells.

It aims to examine diseases that can potentially be treated by stem cells.

Follow this link:
UK biotech PhoreMost to work with Otsuka on gene therapy projects - - pharmaphorum

Personalized Gene Therapy Treatments for Cancer Market 2020-2026: Deep Analysis of Current Trends and Future Demand by Top Key Players – Vital News 24

The latest release from CMIwith title Personalized Gene Therapy Treatments for Cancer Market Research Report 2020-2026 (by Product Type, End-User / Application and Regions / Countries) provides an in-depth assessment of the Personalized Gene Therapy Treatments for Cancer including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. Global Personalized Gene Therapy Treatments for Cancer Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released BY Coherent Market Insights. The report presents a complete assessment of the Market covering future trends, current growth factors, attentive opinions, facts, and industry-validated market data forecast until 2026.

Global Personalized Gene Therapy Treatments for Cancer Market Segmentations

The segmentation chapter allows readers to understand aspects of the Global Personalized Gene Therapy Treatments for Cancer Market such as products/services, available technologies, and applications. These chapters are written in a way that describes years of development and the process that will take place in the next few years. The research report also provides insightful information on new trends that are likely to define the progress of these segments over the next few years.

Free Download PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/60(**Note: Free Sample with TOC, Graph, Charts)

Key companies covered as a part of this study include (Amgen, Inc., SynerGene Therapeutics, Inc., Chengdu Shi Endor Biological Engineering Technology Co., Ltd., Cold Genesys, Inc., Takara Bio, Inc., Bellicum Pharmaceuticals, Inc., Ziopharm Oncology, Inc., OncoSec Medical, Inc., Sevion Therapeutics, Inc., and Burzynski Clinic.)

Global Personalized Gene Therapy Treatments for Cancer Market and Competitive Analysis

Know your current market situation! Not only an important element for new products but also for current products given the ever-changing market dynamics. The study allows marketers to stay in touch with current consumer trends and segments where they can face a rapid market share drop. Discover who you really compete against in the marketplace, with Market Share Analysis know market position, % market Share and Segmented Revenue of Personalized Gene Therapy Treatments for Cancer Market

Segmentation and Targeting

Essential demographic, geographic, psychographic and behavioral information about business segments in the Personalized Gene Therapy Treatments for Cancer market is targeted to aid in determining the features company should encompass in order to fit into the business requirements. For the Consumer-based market the study is also classified with Market Maker information in order to better understand who the clients are, their buying behavior and patterns.

*** For the global version, a list of below countries by region can be added as part of customization at minimum cost.North America (United States, Canada & Mexico).Asia-Pacific (Japan, China, India, Australia, etc).Europe (Germany, UK, France, etc).Central & South America (Brazil, Argentina, etc).Middle East & Africa (United Arab Emirates, Saudi Arabia, South Africa, etc).

Personalized Gene Therapy Treatments for Cancer Product/Service Development

Knowing how the product/services fit the needs of clients and what changes would require to make the product more attractive is the need of an hour. Useful approaches to focus group by utilizing User Testing and User Experience Research. Demand-side analysis always helps to correlate consumer preferences with innovation.

Marketing Communication and Sales Channel

Understanding marketing effectiveness on a continual basis help determine the potential of advertising and marketing communications and allow us to use best practices to utilize an untapped audience. In order to make marketers make effective strategies and identify why the target market is not giving attention, we ensure the Study is Segmented with appropriate marketing & sales channels to identify potential market size by Revenue and Volume* (if Applicable).

Pricing and Forecast

Pricing/subscription always plays an important role in buying decisions; so we have analyzed pricing to determine how customers or businesses evaluate it not just in relation to other product offerings by competitors but also with immediate substitute products. In addition to future sales Separate Chapters on Cost Analysis, Labor*, production* and Capacity are Covered.

How geography and sales fit together

This study is helpful to all operators who want to identify the exact size of their target audience at a specific geographic location. The keywordMarket allows entrepreneurs to determine local markets for business expansion. This study answers the questions below:

1. Where do the requirements come from?2. Where do non-potential customers reside?3. What is the buying behavior of customers in a specific region?4. What is the spending power of the customers in a particular region?

** Have Any Query? Ask Our Industry Expert @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/60

Having our reviews and subscribing our report will help you solve the subsequent issues:

*Uncertainty about the future: Our research and insights help our customers predict the upcoming revenue pockets and growth areas. This will guide customers to invest their resources.

*Understanding market sentiments: It is very important to have a fair understanding of market sentiment for your strategy. Our insights will help you see every single eye on market sentiment. We maintain this analysis by working with key opinion leaders on the value chain of each industry we track.

*Understanding the most reliable investment center: Our research evaluates investment centers in the market, taking into account future demand, profits, and returns. Clients can focus on the most prestigious investment centers through market research.

*Evaluating potential business partners: Our research and insights help our clients in identifying compatible business partners.

Furthermore, the years considered for the study are as follows:

Historical year 2013-2018Base year 2019Forecast period** 2020 to 2026 [** unless otherwise stated]

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj ShahPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]Visit Blog: https://globalindustryresearchblog.wordpress.com/

More:
Personalized Gene Therapy Treatments for Cancer Market 2020-2026: Deep Analysis of Current Trends and Future Demand by Top Key Players - Vital News 24

Archives